Metraipolis › archive › dc_76751cf7c893
Strategic Combinations of Antibody-Drug Conjugates from 2023 to 2025: From Dual Therapies to Innovative ADC-Based Regimens — Europe PMC PMID:41471096
- Source
- Europe PMC (en)
- Original
- https://europepmc.org/article/MED/41471096
- DOI
- 10.3390/pharmaceutics17121581
- License (as archived)
- solo-consultazione
- Archived
- 2026-11-07T19:31:00.736Z
- SHA-256 of the archived text
4138a6f8805de4040d59cb569a79e58ae67600ef4fb5b32428d21c5133dc9971- Stable URL of this page
https://metraipolis.com/documento/dc_76751cf7c893
How to cite
Strategic Combinations of Antibody-Drug Conjugates from 2023 to 2025: From Dual Therapies to Innovative ADC-Based Regimens — Europe PMC PMID:41471096 — Europe PMC (en), https://europepmc.org/article/MED/41471096 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_76751cf7c893 (Metraipolis archive dc_76751cf7c893, sha256 4138a6f8805de4040d59cb569a79e58ae67600ef4fb5b32428d21c5133dc9971)
BibTeX
@misc{dc76751cf7c893,
title = {Strategic Combinations of Antibody-Drug Conjugates from 2023 to 2025: From Dual Therapies to Innovative ADC-Based Regimens — Europe PMC PMID:41471096},
howpublished = {Europe PMC (en)},
url = {https://europepmc.org/article/MED/41471096},
note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_76751cf7c893; sha256 4138a6f8805de4040d59cb569a79e58ae67600ef4fb5b32428d21c5133dc9971},
year = {2026}
}Archived text
The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/41471096. Agents can read the archived copy with the MCP tool read_document.